TY - JOUR
T1 - Prevalence and phenotypes associated with ALPK3 null variants in a large French multicentric cohort
T2 - Confirming its involvement in hypertrophic cardiomyopathy
AU - Ader, Flavie
AU - Jedraszak, Guillaume
AU - Janin, Alexandre
AU - Billon, Clarisse
AU - Buisson, Nathalie Roux
AU - Bloch, Adrien
AU - Bensalah, Meriem
AU - De Sandre-Giovannoli, Anachiara
AU - Goudal, Adeline
AU - Marsili, Luisa
AU - Cazeneuve, Cécile
AU - Charron, Philippe
AU - Millat, Gilles
AU - Richard, Pascale
N1 - Publisher Copyright:
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2024/6
Y1 - 2024/6
N2 - Biallelic disease-causing variants in the ALPK3 gene were first identified in children presenting with a severe cardiomyopathy. More recently, it was shown that carriers of heterozygous ALPK3 null variants are at risk of developing hypertrophic cardiomyopathy (HCM) with an adult onset. Since the number of reported ALPK3 patients is small, the mutational spectrum and clinical data are not fully described. In this multi-centric study, we described the molecular and clinical spectrum of a large cohort of ALPK3 patients. Genetic testing using targeted next generation sequencing was performed in 16 183 cardiomyopathy index cases. Thirty-six patients carried at least one null ALPK3 variant. The five paediatric patients carried two ALPK3 variants, all presented an HCM phenotype with severe outcomes (one transplantation, one heart failure and one cardiac arrest). The 31 adult patients carried heterozygous variants and the main phenotype was HCM (n = 26/31); including 15% (n = 4) presented with an apical or a concentric form of hypertrophy. Reporting a large cohort of ALPK3 patients, this collaborative work confirmed a strong association with HCM and suggesting his screening in the context of idiopathic HCM.
AB - Biallelic disease-causing variants in the ALPK3 gene were first identified in children presenting with a severe cardiomyopathy. More recently, it was shown that carriers of heterozygous ALPK3 null variants are at risk of developing hypertrophic cardiomyopathy (HCM) with an adult onset. Since the number of reported ALPK3 patients is small, the mutational spectrum and clinical data are not fully described. In this multi-centric study, we described the molecular and clinical spectrum of a large cohort of ALPK3 patients. Genetic testing using targeted next generation sequencing was performed in 16 183 cardiomyopathy index cases. Thirty-six patients carried at least one null ALPK3 variant. The five paediatric patients carried two ALPK3 variants, all presented an HCM phenotype with severe outcomes (one transplantation, one heart failure and one cardiac arrest). The 31 adult patients carried heterozygous variants and the main phenotype was HCM (n = 26/31); including 15% (n = 4) presented with an apical or a concentric form of hypertrophy. Reporting a large cohort of ALPK3 patients, this collaborative work confirmed a strong association with HCM and suggesting his screening in the context of idiopathic HCM.
KW - ALPK3
KW - concentric cardiomyopathy
KW - dominant inheritance
KW - hypertrophic cardiomyopathy
UR - http://www.scopus.com/inward/record.url?scp=85191848019&partnerID=8YFLogxK
U2 - 10.1111/cge.14505
DO - 10.1111/cge.14505
M3 - Article
C2 - 38356193
AN - SCOPUS:85191848019
SN - 0009-9163
VL - 105
SP - 676
EP - 682
JO - Clinical Genetics
JF - Clinical Genetics
IS - 6
ER -